Dr. Carolina Haass-Koffler has received a R01 Award ($2.5M) from the NIH/NIAAA. A focus on alpha-1 blockade as a novel pharmacological treatment for alcohol use disorder (AUD). The goal of this study is to understand the role of stress in the development of AUD therapies that target noradrenergic blockade. This study proposes a 16-week, between-subject, double-blind, randomized clinical trial with doxazosin compared to placebo
Dr. Rosemarie Martin, Assistant Professor of Behavioral and Social Sciences, was an invited subject matter expert at National Governor’s Association (NGA) Southeast Regional Medication Assisted Treatment (MAT) workshop. Through a partnership with the American Correctional Association & the CDC, NGA brought 5 states to the table to discuss access to MAT for justice involved populations.
Dr.s Jennifer Tidey, left, and Peter Monti, both professors within Brown University's School of Public Health, will lead a newly funded Center of Biomedical Research Excellence (COBRE) focused on the intersection of substance use and disease.
Dr. Rosemarie Martin was recenly awarded $10.8 million for Opioid Treatment aimed at parolees and people on probation. The research award from the National Institutes of Health (NIH) was made to Brown University School of Public Health for research by Rosemarie Martin, Ph.D., and Damaris Rohsenow, Ph.D., along with Lauren Brinkley-Rubenstein, Ph.D., of University of North Carolina at Chapel Hill.
Dr. Bernstein co-authored an article in BMJ-Evidence Based Medicine, led by Dr. Charlotte Blease at Harvard University. We critique the methodology of open-label placebo trials and argue that the quality of this research depends, in large part, upon the comparison condition. Dr. Blease presented this research, also co-authored by Dr. Cosima Locher (University of Plymouth), as an invited speaker at the Society for Interdisciplinary Placebo studies Conference in Leiden, Netherlands.